Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy

Acute lymphoblastic leukemia (ALL) is a relatively rare disease in adults accounting for no more than 20% of all cases of acute leukemia. By contrast with the pediatric population, in whom significant improvements in long term survival and even cure have been achieved over the last 30years, adult ALL remains a significant challenge. Overall survival in this group remains a relatively poor 20-40%. Modern research has focused on improved pharmacokinetics, novel pharmacogenetics and personalized principles to optimize the efficacy of the treatment while reducing toxicity.

Source: Blood Reviews - January 10, 2015 Category: Hematology Authors: Lin Mei, Evelena P. Ontiveros, Elizabeth A. Griffiths, James E. Thompson, Eunice S. Wang, Meir Wetzler Tags: Review Source Type: research